The FGFR4-G388R Polymorphism Promotes Mitochondrial STAT3 Serine Phosphorylation to Facilitate Pituitary Growth Hormone Cell Tumorigenesis

English version České info

Pituitary tumors are common intracranial neoplasms, yet few germline abnormalities have been implicated in their pathogenesis. Here we show that a single nucleotide germline polymorphism (SNP) substituting an arginine (R) for glycine (G) in the FGFR4 transmembrane domain can alter pituitary cell growth and hormone production. Compared with FGFR4-G388 mammosomatotroph cells that support prolactin (PRL) production, FGFR4-R388 cells express predominantly growth hormone (GH). Growth promoting effects of FGFR4-R388 as evidenced by enhanced colony formation was ascribed to Src activation and mitochondrial serine phosphorylation of STAT3 (pS-STAT3). In contrast, diminished pY-STAT3 mediated by FGFR4-R388 relieved GH inhibition leading to hormone excess. Using a knock-in mouse model, we demonstrate the ability of FGFR4-R385 to promote GH pituitary tumorigenesis. In patients with acromegaly, pituitary tumor size correlated with hormone excess in the presence of the FGFR4-R388 but not the FGFR4-G388 allele. Our findings establish a new role for the FGFR4-G388R polymorphism in pituitary oncogenesis, providing a rationale for targeting Src and STAT3 in the personalized treatment of associated disorders.

Vyšlo v časopise: The FGFR4-G388R Polymorphism Promotes Mitochondrial STAT3 Serine Phosphorylation to Facilitate Pituitary Growth Hormone Cell Tumorigenesis. PLoS Genet 7(12): e32767. doi:10.1371/journal.pgen.1002400
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002400

Souhrn

Zdroje

1. EzzatSAsaSLCouldwellWTBarrCEDodgeWE 2004 The prevalence of pituitary adenomas: a systematic review. Cancer 101 613 619

2. AsaSLEzzatS 2002 The pathogenesis of pituitary tumours. Nat Rev Cancer 2 836 849

3. AsaSLEzzatS 2009 The pathogenesis of pituitary tumors. Annu Rev Pathol 4 97 126

4. VallarLSpadaAGiannattasioG 1987 Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330 566 568

5. LandisCAMastersSBSpadaAPaceAMBourneHR 1989 GTPase inhibiting mutations activate the alpha-chain of Gs and stimulate adenylate cyclase in human pituitary tumors. Nature 340 692 696

6. ChandrasekharappaSCGuruSCManickamPOlufemiSECollinsFS 1997 Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 404 407

7. ZhuangZEzzatSVortmeyerAOWeilROldfieldEH 1997 Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res 57 5446 5451

8. DalyAFVanbellinghenJFKhooSKJaffrain-ReaMLNavesLA 2007 Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92 1891 1896

9. KirschnerLSCarneyJAPackSDTaymansSEGiatzakisC 2000 Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26 89 92

10. GejmanRBatistaDLZhongYZhouYZhangX 2008 Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 93 4119 4125

11. RevillKDudleyKJClaytonRNMcNicolAMFarrellWE 2009 Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma. Endocr Relat Cancer 16 537 548

12. ScullyKMRosenfeldMG 2002 Pituitary development: regulatory codes in mammalian organogenesis. Science 295 2231 2235

13. De MoerloozeLSpencer-DeneBRevestJHajihosseiniMRosewellI 2000 An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Develop 127 483 492

14. CelliGLaRochelleWJMackemSSharpRMerlinoG 1998 Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J 17 1642 1655

15. EzzatSSmythHSRamyarLAsaSL 1995 Heterogeneous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 80 878 884

16. AbbassSAAAsaSLEzzatS 1997 Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab 82 1160 1166

17. EzzatSZhengLZhuXFWuGEAsaSL 2002 Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109 69 78

18. YuSAsaSLWeigelRJEzzatS 2003 Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. J Biol Chem 278 19597 19602

19. EzzatSYuSAsaSL 2003 Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5′ fibroblast growth factor receptor-4 promoter. Am J Pathol 163 1177 1184

20. EzzatSZhengLAsaSL 2004 Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 18 2543 2552

21. BangeJPrechtlDCheburkinYSpechtKHarbeckN 2002 Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62 840 847

22. ThussbasCNahrigJStreitSBangeJKrinerM 2006 FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24 3747 3755

23. WangJStocktonDWIttmannM 2004 The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10 6169 6178

24. MorimotoYOzakiTOuchidaMUmeharaNOhataN 2003 Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98 2245 2250

25. StreitSBangeJFichtnerAIhrlerSIssingW 2004 Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111 213 217

26. HartKCRobertsonSCKanemitsuMYMeyerANTynanJA 2000 Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 29 3309 3320

27. ReichNC 2009 STAT3 revs up the powerhouse. Sci Signal 2 e61

28. SeitzerNMayrTStreitSUllrichA 2010 A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 70 802 812

29. AsaSL 2001 Transgenic and knockout mouse models clarify pituitary development, function and disease. Brain Pathol 11 371 383

30. EswarakumarVPLaxISchlessingerJ 2005 Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16 139 149

31. TakedaKAkiraS 2000 STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11 199 207

32. ChungJUchidaEGrammerTCBlenisJ 1997 STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 17 6508 6516

33. GreenhalghCJBertolinoPAsaSLMetcalfDCorbinJE 2002 Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol 16 1394 1406

34. SchuffKGHentgesSTKellyMABinartNKellyPA 2002 Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J Clin Invest 110 973 981

35. AsaSLDiGiovanniRJiangJWardMLLoeschK 2007 A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67 7505 7511

36. RossRJ 1999 The GH receptor and GH insensitivity. Growth Horm IGF Res 9 Suppl B 42 45

37. MelmedSYamashitaSYamasakiHFaginJNambaH 1996 IGF-I receptor signalling: lessons from the somatotroph. Recent Prog Horm Res 51 189 215

38. ShenYSchlessingerKZhuXMeffreEQuimbyF 2004 Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 24 407 419

39. YuHJoveR 2004 The STATs of cancer–new molecular targets come of age. Nat Rev Cancer 4 97 105

40. GoughDJCorlettASchlessingerKWegrzynJLarnerAC 2009 Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324 1713 1716

41. EzzatSZhengLWinerDAsaSL 2006 Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications. Mol Endocrinol 20 2965 2975

42. LindauerMHochhausA 2010 Dasatinib. Recent Results Cancer Res 184 83 102

43. KimLCSongLHauraEB 2009 Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6 587 595

44. JenkinsPJBustinSA 2004 Evidence for a link between IGF-I and cancer. Eur J Endocrinol 151 Suppl 1 S17 S22

45. AsaSL 2011 Tumors of the Pituitary Gland. Armed Forces Institute of Pathology. Atlas of Tumor Pathology. Fourth Series, Fascicle 15. ARP Press, Washington, DC